NasdaqCM - Nasdaq Real Time Price USD

Biodexa Pharmaceuticals Plc (BDRX)

Compare
5.67 -2.73 (-32.50%)
As of 2:23 PM EDT. Market Open.

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Stephen A. Stamp CEO, CFO, Company Secretary & Director 334.06k -- 1962
Dr. Daniel Palmer MBA, Ph.D. Vice President of Technology -- -- --
Ms. Nicola Tuckwell VP & Head of Clinical Operations -- -- --
Mr. Steve Ellul Chief Business Officer -- -- --
Ms. Fiona Sharp Group Financial Controller -- -- --

Biodexa Pharmaceuticals Plc

1 Caspian Point
Caspian Way
Cardiff, CF10 4DQ
United Kingdom
44 29 2048 0180 https://www.biodexapharma.com
Sector:?
Healthcare
Industry:?
Biotechnology
Full Time Employees:?
21

Description

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Corporate Governance

Biodexa Pharmaceuticals Plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

October 15, 2024 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

October 4, 2024 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

September 26, 2024 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

September 19, 2024 at 12:00 AM UTC

F-6 POS: Offering Registrations

September 16, 2024 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

August 30, 2024 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

August 15, 2024 at 12:00 AM UTC

CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission

August 12, 2024 at 12:00 AM UTC

F-1: Offering Registrations

August 1, 2024 at 12:00 AM UTC

D: Additional Forms

July 23, 2024 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

Related Tickers